Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.47 |
| ▸ | WDR5 | P61964 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5535918 | 0.88 | PLAU (0.50) | MEN1KMT2ALMNACA12CA1 | |
| SCHEMBL5532391 | 0.81 | DGAT1 (0.46) | ALDH1A1KDM4EGAAHPGDSMN1; SMN2 | |
| SCHEMBL5531200 | 0.76 | CHEK1 (0.54) | ALDH1A1KDM4ELMNATDP1HSD17B10 | |
| SCHEMBL12360763 | 0.76 | ERBB2 (0.54) | MYCWDR5ALDH1A1KDM4EMAPT | |
| SCHEMBL5533628 | 0.75 | SYK (0.42) | ALDH1A1KDM4EMAPK1DHODHHPGD | |
| SCHEMBL30079151 | 0.74 | CA1 (0.57) | MYCWDR5ALDH1A1KDM4EMAPT | |
| SCHEMBL5533583 | 0.74 | CNR2 (0.40) | ALDH1A1KDM4EMAPTLMNAPTPN1 | |
| Biphenyl Dimethyl Dicarboxylate SCHEMBL2890577 | 0.73 | CA1 (0.67) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL16519646 | 0.73 | ERBB2 (0.40) | ALDH1A1KDM4EMAPTKMT2AGAA | |
| SCHEMBL7401479 | 0.73 | CA1 (0.53) | MAPTTDP1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2234978-B1 | CARBAMOYL COMPOUNDS AS DGAT1 INHIBITORS 190 | ASTRAZENECA AB (SE) | 2015-02-25 | — | — | EP | disclosed |
| EP-2234978-B1 | CARBAMOYL COMPOUNDS AS DGAT1 INHIBITORS 190 | ASTRAZENECA AB (SE) | 2015-02-25 | — | — | EP | disclosed |
| US-20120108602-A1 | Carbamoyl Compounds as DGAT1 Inhibitors 190 | ASTRAZENECA AB (SE) | 2012-05-03 | — | — | US | disclosed |
| US-20120108602-A1 | Carbamoyl Compounds as DGAT1 Inhibitors 190 | ASTRAZENECA AB (SE) | 2012-05-03 | — | — | US | disclosed |
| US-20120108602-A1 | Carbamoyl Compounds as DGAT1 Inhibitors 190 | ASTRAZENECA AB (SE) | 2012-05-03 | — | — | US | disclosed |
| US-7994179-B2 | Carbamoyl compounds as DGAT1 inhibitors 190 | ASTRAZENECA AB (SE) | 2011-08-09 | — | — | US | disclosed |
| US-7994179-B2 | Carbamoyl compounds as DGAT1 inhibitors 190 | ASTRAZENECA AB (SE) | 2011-08-09 | — | — | US | disclosed |
| US-7994179-B2 | Carbamoyl compounds as DGAT1 inhibitors 190 | ASTRAZENECA AB (SE) | 2011-08-09 | — | — | US | disclosed |
| EP-2234978-A1 | CARBAMOYL COMPOUNDS AS DGAT1 INHIBITORS 190 | AstraZeneca AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| US-20090298853-A1 | Carbamoyl Compounds as DGAT1 Inhibitors 190 | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
| US-20090298853-A1 | Carbamoyl Compounds as DGAT1 Inhibitors 190 | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
| US-20090298853-A1 | Carbamoyl Compounds as DGAT1 Inhibitors 190 | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
| WO-2009081195-A1 | CARBAMOYL COMPOUNDS AS DGAT1 INHIBITORS 190 | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009081195-A1 | CARBAMOYL COMPOUNDS AS DGAT1 INHIBITORS 190 | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108602-A1 | Carbamoyl Compounds as DGAT1 Inhibitors 190 | DGAT1, DGAT2, SOAT1 | MYC 2476/4885WDR5 3893/4885ALDH1A1 277/4885 |
| US-20090298853-A1 | Carbamoyl Compounds as DGAT1 Inhibitors 190 | DGAT1, DGAT2, SOAT1 | MYC 2461/4885WDR5 3915/4885ALDH1A1 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.